Alector, Inc.

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:38:09 2024-05-14 am EDT			5-day change	1st Jan Change
5.395 ^USD	+0.09%		+1.60%	-32.52%

May. 08	Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	CI
May. 08	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Alector, Inc. Announces Appointment of Elizabeth A. Garofalo to Its Board of Directors

September 28, 2021 at 08:30 am EDT

Alector, Inc. announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company’s Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology.

Latest news about Alector, Inc.

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024	May. 08	CI
Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	Apr. 16	CI
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	Apr. 16	CI
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	Apr. 16	CI
Alector, Inc. Announces Board Changes	Mar. 21	CI
Transcript : Alector, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	Mar. 13
Transcript : Alector, Inc., 2023 Earnings Call, Feb 27, 2024	Feb. 27
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	Feb. 27	CI
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	Feb. 08	CI
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	Feb. 07	MT
GSK: breakthrough therapy status in dementia	Feb. 07	CF
Alector, GSK Get FDA Breakthrough Designation for Latozinemab	Feb. 07	DJ
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	Feb. 07	CI
Alector Closes $75 Million Public Stock Offering	Jan. 19	MT
Alector Tumbles After Pricing $75 Million Stock Offering	Jan. 17	MT
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday	Jan. 17	MT
Alector Plans Common Stock Offering; Shares Fall After-Hours	Jan. 16	MT
North American Morning Briefing : Volatility -2-	Dec. 15	DJ
Alector Shares Rise After Stifel Upgrade	Dec. 14	MT
Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	Dec. 14	MT
Transcript : Alector, Inc. - Special Call	Dec. 13
Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	Dec. 12	MT

Chart Alector, Inc.

Duration

Period

More charts

Company Profile

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Sector

Biotechnology & Medical Research

Calendar

11:55am - BofA Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alector, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.39 USD

Average target price

15.44 USD

Spread / Average Target

+186.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALECTOR, INC.	-32.52%	520M
VERTEX PHARMACEUTICALS INCORPORATED	+4.35%	111B
REGENERON PHARMACEUTICALS, INC.	+11.11%	105B
BIONTECH SE	-12.16%	22.34B
ARGENX SE	-3.90%	21.93B
GENMAB A/S	-5.99%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-9.94%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.40%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.45%	12.45B

Bio Therapeutic Drugs